The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10832 malaria professionals are enjoying the free benefits of MalariaWorld today

randomized controlled trial

Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial

August 11, 2020 - 07:39 -- Open Access
Tags: 
intermittent preventive treatment, IPTp, dihydroartemisinin-piperaquine, sulfadoxine-pyrimethamine, malaria, randomized controlled trial, pregnant women
Author(s): 
Kakuru A, Jagannathan P, Dorsey G, et al.
Reference: 
BMC Med. 2020 Aug 10;18(1):207

Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) significantly reduces the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (SP), the current standard of care, but its impact on the incidence of malaria during infancy is unknown.

Does improving appropriate use of malaria medicines change population beliefs in testing and treatment? Evidence from a randomized controlled trial

March 9, 2020 - 15:10 -- Open Access
Tags: 
malaria, medicines, randomized controlled trial
Author(s): 
Maffioli EM, Mohanan M, Saran I, O'Meara WP
Reference: 
Health Policy Plan. 2020 Mar 4. pii: czaa010

A major puzzle in malaria treatment remains the dual problem of underuse and overuse of malaria medications, which deplete scarce public resources used for subsidies and lead to drug resistance. One explanation is that health behaviour, especially in the context of incomplete information, could be driven by beliefs, pivotal to the success of health interventions. The objective of this study is to investigate how population beliefs change in response to an experimental intervention which was shown to improve access to rapid diagnostic testing (RDT) through community health workers (CHWs) and to increase appropriate use of anti-malaria medications.

In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso

January 7, 2020 - 15:14 -- Open Access
Tags: 
In vivo/ex vivo, efficacy, artemether–lumefantrine, artesunate–amodiaquine, first-line treatment, uncomplicated falciparum, malaria, children, randomized controlled trial, Burkina Faso
Author(s): 
Moussa Lingani, Léa Nadège Bonkian, Halidou Tinto, et al.
Reference: 
Malaria Journal 2020 19:8, 6 January 2020

Artemisinin-based combination therapy (ACT) is recommended to improve malaria treatment efficacy and limit drug-resistant parasites selection in malaria endemic areas. 5 years after they were adopted, the efficacy and safety of artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ), the first-line treatments for uncomplicated malaria were assessed in Burkina Faso.

Subscribe to RSS - randomized controlled trial